Sio Gene to File for Declare an Liquidating Distribution of $0.435 Per Share
Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results
Following a monthslong business review, Sio Gene Therapies revealed Thursday plans to shut down the company and liquidate its assets.
Sio Gene Therapies Inc. Announces Board Approval of Plan of Complete Liquidation and Dissolution
NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX) today provided financial results for its fiscal second quarter ended September 30, 2022.
Sio Gene Therapies Announces Fiscal First Quarter 2022 Financial Results
NEW YORK and DURHAM, N.C., June 14, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX) today provided financial results for its fiscal year ended March 31, 2022. Fiscal Fourth...
Sio Gene Therapies Provides Corporate Update
NEW YORK and DURHAM, N.C., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today provided corporate updates and financial results for its fiscal third quarter ended December 31, 2021.